Cargando…

Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease

BACKGROUND: Whether hyperkalaemia in CKD is chronic or transient, and whether this has different outcome implications, is not known. METHODS: This was an observational study of adults with CKD G3–5 from Stockholm, Sweden 2006–11. We examined individual trajectories of potassium from all measurements...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trevisan, Marco, Clase, Catherine M, Evans, Marie, Popov, Tamara, Ludvigsson, Jonas F, Sjölander, Arvid, Carrero, Juan Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757415/ https://www.ncbi.nlm.nih.gov/pubmed/35035946 http://dx.doi.org/10.1093/ckj/sfab159

Ejemplares similares

Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…
por: Carrero, Juan Jesus, et al.
Publicado: (2023)

Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study
por: Laureati, Paola, et al.
Publicado: (2019)

Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease
por: Mazhar, Faizan, et al.
Publicado: (2022)

Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
por: Trevisan, Marco, et al.
Publicado: (2018)

Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study
por: Xu, Yang, et al.
Publicado: (2021)

Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function
por: Cupisti, Adamasco, et al.
Publicado: (2018)

Absolute and Relative Risks of Kidney Outcomes Associated With Lithium vs Valproate Use in Sweden
por: Bosi, Alessandro, et al.
Publicado: (2023)

Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, Eberhard, et al.
Publicado: (2013)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, E., et al.
Publicado: (2013)

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
por: Ward, Thomas, et al.
Publicado: (2022)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study
por: Fu, Edouard L, et al.
Publicado: (2021)

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021)

Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients
por: Smyrli, Maria, et al.
Publicado: (2021)

Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project
por: Alkas, Jim, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction
por: Trevisan, Marco, et al.
Publicado: (2020)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Surreptitious hyperkalaemia and its complications
por: Morgenstern, Tilo, et al.
Publicado: (2009)

Potassium homoeostasis and pathophysiology of hyperkalaemia
por: Kjeldsen, Keld Per, et al.
Publicado: (2019)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Suxamethonium-chloride: Hyperkalaemia: case report
Publicado: (2021)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
por: Slawik, Jonathan, et al.
Publicado: (2020)

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care
por: Provenzano, Michele, et al.
Publicado: (2018)

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
por: Humphrey, Toby, et al.
Publicado: (2021)

Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study
por: Xu, Hong, et al.
Publicado: (2021)

Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREAtinine Measurement project
por: Runesson, Björn, et al.
Publicado: (2019)

Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
por: Turakhia, Mintu P, et al.
Publicado: (2018)

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
por: Kanji, Tahir, et al.
Publicado: (2015)

Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project
por: Su, Guobin, et al.
Publicado: (2019)

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis
por: Wernroth, Mona-Lisa, et al.
Publicado: (2020)

Irritable bowel syndrome and Parkinson’s disease risk: register-based studies
por: Liu, Bojing, et al.
Publicado: (2021)

Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis
por: Evans, Marie, et al.
Publicado: (2020)

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pvfcmksacp61e6v4b94416e8m6